Skip to content

3 Biotech Stocks You’ll Regret Not Buying Soon

The biotech industry proved itself resilient in the face of the COVID-19 pandemic. With research from Mckinsey, venture capitalist (VC) companies increased investments from 2,200 in 2016 to 3,100 in 2021 in biotechnology (biotech) startups.

These startups have advanced medicine overall, improving cell therapy, tissue regeneration, genetic medicine, and more. With increasing innovation, we see an ongoing cycle. VC companies will continue to invest by providing resources and funding for these companies. The future of this industry is set for long-term growth.

These three stocks are set to grow based on the innovative breakthroughs and maintenance of stellar financials in macroeconomic headwinds.

This post appeared first on InvestorPlace.